Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()

Antiangiogenic therapy has shown promising results in preclinical and clinical trials. However, tumor cells acquire resistance to this therapy by gaining ability to survive and proliferate under hypoxia induced by antiangiogenic therapy. Combining antiangiogenic therapy with hypoxia-activated prodru...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Kumar, Sushil, Sun, Jessica D., Zhang, Libo, Mokhtari, Reza Bayat, Wu, Bing, Meng, Fanying, Liu, Qian, Bhupathi, Deepthi, Wang, Yan, Yeger, Herman, Hart, Charles, Baruchel, Sylvain
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2018
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6041570/
https://ncbi.nlm.nih.gov/pubmed/29803017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2018.05.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados